UK-based firm GlaxoSmithKline (GSK) has selected a third target as part of its ongoing oncology discovery partnership with Immunocore for multiple novel targets not addressable with antibody-based technologies.

Immunocore is a T-cell receptor (TCR) company that develops biological drugs to treat cancer, infectious diseases and autoimmune diseases.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

As part of the collaboration, Immunocore will produce a new ImmTAC molecule against the selected target that is relevant in multiple cancers.

Immunocore chief scientific officer Dr Bent Jakobsen said: “The initiation of this new programme adds to a growing body of evidence that our ImmTAC technology has real potential to generate novel, potent drug candidates against disease targets, which are difficult to address with other biologic platforms.

"The initiation of this new programme adds to a growing body of evidence that our ImmTAC technology has real potential to generate novel, potent drug candidates against disease targets, which are difficult to address with other biologic platforms."

“ImmTAC molecules are relevant across a wide range of cancer types and have the ability to tackle solid 'cold', low mutation rate tumours – the majority of tumours which are difficult for other immuno-oncology drugs to address.”

See Also:

The current project is the third programme to be initiated as part of the discovery collaboration with GSK that was announced in 2013.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the agreement, Immunocore is working on two other ImmTAC programmes, of which the lead project is on track for an Investigational New Drug (IND) this year with potential application in Non-Small Cell Lung Cancer (NSCLC), bladder cancer, synovial sarcoma, melanoma, and ovarian cancer.

GSK Immuno-Oncology senior vice-president, Therapeutic Area head and Oncology Research and Development head Dr Axel Hoos said: “ImmTAC molecules have great potential among the third generation of immuno-oncology agents and we look forward to seeing this promising programme progress.”